Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT03840200
- Locations
- 🇦🇺
Macquarie University Hospital, Macquarie Park, New South Wales, Australia
🇪🇸Clínica Universidad de Navarra, Pamplona, Navarra, Spain
🇮🇹Azienda Ospedaliera Santa Maria di Terni, Terni, Umbria, Italy
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 236
- Registration Number
- NCT03842969
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸CenExel Rocky Mountain Clinical Research, LLC, Englewood, Colorado, United States
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 671
- Registration Number
- NCT03823287
- Locations
- 🇵🇱
Dobry Wzrok Sp Z O O, Gdańsk, Poland
🇵🇱Gabinet Okulistyczny Prof Edward Wylegala, Katowice, Poland
🇵🇱SPEKTRUM Osrodek Okulistyki Klinicznej, Wroclaw, Poland
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 658
- Registration Number
- NCT03823300
- Locations
- 🇦🇷
Centro Oftalmológico Dr. Charles S.A., Capital Federal, Argentina
🇵🇹Hospital de Sao Joao; Servico de Oftalmologia, Porto, Portugal
🇺🇸The Retina Care Center, Baltimore, Maryland, United States
An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT03817853
- Locations
- 🇳🇱
Albert Schweitzer Ziekenhuis - loc Dordrecht, Dordrecht, Netherlands
🇧🇷NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil
🇺🇸San Juan Oncology Associates, Farmington, New Mexico, United States
Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects
- Conditions
- Interventions
- Drug: Balovaptan therapeutic dose Treatment ADrug: Balovaptan supra-therapeutic dose Treatment BDrug: Active control [moxifloxacin] on Day 2 Treatment CDrug: Active control [Moxifloxacin] on Day 15 Treatment DDrug: Placebo for Balovaptan Treatment CDrug: Placebo for Balovaptan Treatment DDrug: Placebo for Moxifloxacin Treatment ADrug: Placebo for Moxifloxacin Treatment BDrug: Moxifloxacin Treatment CDrug: Placebo for Moxifloxacin Treatment DDrug: Moxifloxacin Treatment DDrug: Placebo for Moxifloxacin Treatment C
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 57
- Registration Number
- NCT03808298
- Locations
- 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 139
- Registration Number
- NCT03800836
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇦🇺St Vincents Hospital; Cardiopulmonary transplant Ambulatory Care Dept, Darlinghurst, New South Wales, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2756
- Registration Number
- NCT03782207
- Locations
- 🇧🇬
Multiprofile Hospital for Active Treatment Uni Hospital, Panagyurishte, Bulgaria
🇧🇬Umhat Dr Georgi Stranski, Pleven, Bulgaria
🇧🇬University Hospital Palmed, Plovdiv, Bulgaria
A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 26
- Registration Number
- NCT03779334
- Locations
- 🇵🇱
Szpital Gdanskiego Uniwersytetu Medycznego; Clinic of developmental neurology, Gda?sk, Poland
🇨🇳Kaohsiung Medical University Chung-Ho Hospital; Pediatric Neurology, Kaohsiung, Taiwan
🇺🇸Nemours Children's Hospital, Orlando, Florida, United States
A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 14
- Registration Number
- NCT03774576
- Locations
- 🇫🇷
BIOTRIAL, Rennes, France